Click the blue text above to follow for more exciting content What is CAR-T Cell Therapy? CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a type of immunotherapy primarily used for the clinical treatment of malignant blood diseases and tumors. CAR-T therapy involves collecting and isolating T cells from the patient’s blood, followed by genetic … Read more
Overview The POLE gene belongs to the DNA polymerase B family and is a catalytic subunit of DNA polymerase ε, possessing 5’→3’ DNA polymerase activity and 3’→5’ exonuclease activity, which play a crucial role in DNA replication and proofreading. Mutations in the exonuclease domain of this gene, which includes exons 9 to 14, can lead … Read more
Published in: Am J Hematol. 2022;97:514–518 Translated by: Ye Xiangjun Since 2001, under the auspices of the World Health Organization (WHO) and its affiliated International Agency for Research on Cancer (IARC), the classification of hematologic tumors has been standardized as part of the WHO classification series commonly referred to as the “WHO Blue Book.” Before … Read more
The exact cause of intrahepatic cholangiocarcinoma (ICC) remains unclear. Well-known risk factors for ICC include congenital choledochal cysts, chronic cholangitis, inflammatory bowel disease, primary sclerosing cholangitis, parasitic infections, chemical carcinogens (such as thorium dioxide and nitrosamines), genetic factors, biliary cirrhosis, cholelithiasis, alcoholic liver disease, and non-specific liver cirrhosis. Recently, studies have found a close association … Read more
After nearly 30 years of development, the ADC platform has been established, with 12 approved products by the FDA and many more in development. This article aims to provide guidance for clinical researchers on the effective design of clinical protocols and the lessons learned from ADCs. 01Introduction In cancer treatment, compared to novel immunotherapy targets … Read more
With the recent approvals of Trastuzumab emtansine (T-DM1) and Gemtuzumab ozogamicin in China, the review of Trastuzumab deruxtecan (T-DXd, DS-8201) is progressing steadily, marking the arrival of a “future” where antibody-drug conjugates (ADCs) greatly benefit breast cancer patients in China. ADCs achieve “precision targeting” of tumors and are referred to as “magic bullets,” changing the … Read more
Following the era of chemotherapy, targeted therapy, and immunotherapy, cytotoxic drugs conjugated with targeted monoclonal antibodies have opened a new era in tumor treatment with the ADC drug class, achieving remarkable results. They have now become a significant category of new drugs in cancer treatment both domestically and internationally. So what exactly are ADC drugs? … Read more
Introduction Antibody-drug conjugate (ADC) therapy has rapidly developed over the past few decades, with 14 products approved globally and over 140 ADCs currently in clinical trials. By 2030, the ADC market is expected to exceed $15 billion. The basic principle of ADCs: by combining the specificity of monoclonal antibodies with the cytotoxicity of effective small … Read more
Recommended Articles:Collect | “Guidelines for Patients with Primary Liver Cancer by the Chinese Anti-Cancer Association”“Collection of 28 Guidelines for Rational Drug Use in Common Diseases at the Grassroots Level (Download PDF)” “Collection of 82 Guidelines for Diagnosis and Treatment of Common Diseases at the Grassroots Level” Protective Equipment Donning and Doffing Video (National Health Commission … Read more
The 65th Annual Meeting of the American Society of Hematology (ASH) will be held in San Diego, USA, from December 9 to 12, 2023. Professor Jiang Qian’s team summarizes the 2023 ASH Continuing Education on Chronic Myeloid Leukemia (CML) to share with everyone. Today, we present the article: Accelerated Phase of Chronic Myeloid Leukemia (CML) … Read more